Highlights of This Issue 235

CELL CYCLE AND SENESCENCE

237 Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth
Xiangnan Guan, Kyle M. LaPak, Rebecca C. Hennessey, Christina Y. Yu, Reena Shakya, Jianying Zhang, and Christin E. Burd

CELL DEATH AND SURVIVAL

250 Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma
Lindsay DeVorkin, Matthew Hattersley, Paul Kim, Jenna Ries, Jaelene Spowart, Michael S. Anglesio, Samuel M. Levi, David G. Huntsman, Ravi K. Amaravadi, Jeffrey D. Winkler, Anna V. Tinker, and Julian J. Lum

DNA DAMAGE AND REPAIR

269 DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy
Antonia A. Nemec, Laura Abriola, Jane S. Merkel, Elisa de Stanchina, Michelle DeVeaux, Daniel Zelterman, Peter M. Glazer, and Joann B. Sweasy

ONCOGENES AND TUMOR SUPPRESSORS

294 LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell–like Transcriptional Program in AML
Jianbiao Zhou, Zit-Liang Chan, Chonglei Bi, Xiao Lu, Phyllis S.Y. Chong, Jing-Yuan Chooi, Lip-Lee Cheong, Shaw-Cheng Liu, Ying Qing Ching, Yafeng Zhou, Motomi Osato, Tuan Zee Tan, Chiu Hin Ng, Siok-Bian Ng, Shi Wang, Qi Zeng, and Wee-Joo Chng

304 Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC

317 Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
Tyler M. Foley, Susan N. Payne, Cheri A. Pasch, Alex E. Yueh, Dana R. Van De Hey, Demetra P. Korkos, Linda Clipson, Molly E. Maher, Kristina A. Matkowskjy, Michael A. Newton, and Dustin A. Deming

328 Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation
Xiaolei Nie, Guangan He, and Zahid H. Siddik

SIGNAL TRANSDUCTION

340 Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors
Monica E. Wielgos, Rajani Rajbandari, Tiffany S. Cooper, Shi Wei, Susan Nozell, and Eddy S. Yang

348 Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma
Fen Zhu, Byounghoon Hwang, Shigeki Miyamoto, and Lixin Rui

RETRACTION

358 Retraction: Nek6 Mediates Human Cancer Cell Transformation and Is a Potential Cancer Therapeutic Target

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Dual hybrid $^{18}$F-fluorodeoxyglucose (FDG) microPET/CT imaging was performed on transgenic mice with Apc and Pik3ca-mutant intestinal adenocarcinomas. These mice were imaged before and following 14 days of treatment with the dual PI3K/mTOR inhibitors BEZ235 and LY3023414. These images demonstrated reductions in the total tumor volume and avidity in those mice treated with agents. Please see the article by Foley and colleagues (beginning on page 317) for more information.